Autologous Platelet Rich Plasma Injection for Headache

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Headache+2 More
Autologous Platelet Rich Plasma Injection - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a single injection of platelet-rich plasma (PRP) can help people with post-traumatic greater occipital neuralgia.

Eligible Conditions
  • Headache
  • Occipital Neuralgia

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Pre-injection, 1 month, and 3 month follow-ups.

Month 3
Change in headache frequency (days per month with headache).
Change in headache severity as measured by the Numerical Pain Raiting Scale (NPRS)
Medication Usage
Number of adverse events
Month 3
Quality of Life in Following Brain Injury Questionnaire
Month 3
Headache Impact Test-6

Trial Safety

Trial Design

3 Treatment Groups

Standard Treatment
1 of 3
Autologous Platelet Rich Plasma Injection
1 of 3
Normal Saline
1 of 3
Active Control
Experimental Treatment
Non-Treatment Group

35 Total Participants · 3 Treatment Groups

Primary Treatment: Autologous Platelet Rich Plasma Injection · Has Placebo Group · Phase 1

Autologous Platelet Rich Plasma Injection
Biological
Experimental Group · 1 Intervention: Autologous Platelet Rich Plasma Injection · Intervention Types: Biological
Standard Treatment
Drug
ActiveComparator Group · 1 Intervention: Depo-Medrol and lidocaine · Intervention Types: Drug
Normal Saline
Other
PlaceboComparator Group · 1 Intervention: Normal Saline · Intervention Types: Other

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: pre-injection, 1 month, and 3 month follow-ups.

Who is running the clinical trial?

University of CalgaryLead Sponsor
701 Previous Clinical Trials
492,856 Total Patients Enrolled
4 Trials studying Headache
409 Patients Enrolled for Headache

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References